Annual SG&A
$55.04 M
+$11.21 M+25.57%
31 December 2023
Summary:
Kymera Therapeutics annual selling, general & administrative expenses is currently $55.04 million, with the most recent change of +$11.21 million (+25.57%) on 31 December 2023. During the last 3 years, it has risen by +$36.81 million (+201.88%). KYMR annual SG&A is now at all-time high.KYMR Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$15.46 M
-$1.92 M-11.04%
30 September 2024
Summary:
Kymera Therapeutics quarterly selling, general & administrative expenses is currently $15.46 million, with the most recent change of -$1.92 million (-11.04%) on 30 September 2024. Over the past year, it has increased by +$1.33 million (+9.45%). KYMR quarterly SG&A is now -11.04% below its all-time high of $17.37 million, reached on 30 June 2024.KYMR Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$2.42 B
-$167.47 M-7.45%
30 September 2024
Summary:
Kymera Therapeutics TTM selling, general & administrative expenses is currently -$2.42 billion, with the most recent change of -$167.47 million (-7.45%) on 30 September 2024. Over the past year, it has dropped by -$2.47 billion (-4704.94%). KYMR TTM SG&A is now -3059.06% below its all-time high of $61.43 million, reached on 30 September 2024.KYMR TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KYMR Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +25.6% | +9.4% | -4704.9% |
| 3 y3 years | +201.9% | +44.9% | -8210.4% |
| 5 y5 years | +1359.2% | +929.6% | -10000.0% |
KYMR Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +201.9% | -11.0% | +46.4% | -282.1% | at low |
| 5 y | 5 years | at high | +1359.2% | -11.0% | +929.6% | -3059.1% | at low |
| alltime | all time | at high | +1359.2% | -11.0% | +929.6% | -3059.1% | at low |
Kymera Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $15.46 M(-11.0%) | $61.43 M(+2.2%) |
| June 2024 | - | $17.37 M(+20.9%) | $60.09 M(+5.7%) |
| Mar 2024 | - | $14.37 M(+1.0%) | $56.85 M(+3.3%) |
| Dec 2023 | $55.04 M(+25.6%) | $14.23 M(+0.8%) | $55.04 M(+4.9%) |
| Sept 2023 | - | $14.12 M(-0.1%) | $52.45 M(+7.3%) |
| June 2023 | - | $14.13 M(+12.4%) | $48.89 M(+6.8%) |
| Mar 2023 | - | $12.56 M(+8.0%) | $45.79 M(+4.5%) |
| Dec 2022 | $43.83 M(+20.6%) | $11.64 M(+10.2%) | $43.83 M(-0.2%) |
| Sept 2022 | - | $10.56 M(-4.3%) | $43.94 M(-0.3%) |
| June 2022 | - | $11.03 M(+4.0%) | $44.05 M(+7.3%) |
| Mar 2022 | - | $10.61 M(-9.6%) | $41.05 M(+12.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | $36.34 M(+99.3%) | $11.74 M(+10.1%) | $36.34 M(+22.0%) |
| Sept 2021 | - | $10.67 M(+32.9%) | $29.78 M(+14.8%) |
| June 2021 | - | $8.03 M(+35.9%) | $25.95 M(+20.2%) |
| Mar 2021 | - | $5.91 M(+14.2%) | $21.58 M(+18.4%) |
| Dec 2020 | $18.23 M(+128.5%) | $5.17 M(-24.3%) | $18.23 M(+17.0%) |
| Sept 2020 | - | $6.84 M(+86.8%) | $15.59 M(+52.1%) |
| June 2020 | - | $3.66 M(+43.1%) | $10.25 M(+55.6%) |
| Mar 2020 | - | $2.56 M(+1.1%) | $6.59 M(+63.5%) |
| Dec 2019 | $7.98 M(+111.6%) | $2.53 M(+68.6%) | $4.03 M(+168.6%) |
| Sept 2019 | - | $1.50 M | $1.50 M |
| Dec 2018 | $3.77 M | - | - |
FAQ
- What is Kymera Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Kymera Therapeutics?
- What is Kymera Therapeutics annual SG&A year-on-year change?
- What is Kymera Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Kymera Therapeutics?
- What is Kymera Therapeutics quarterly SG&A year-on-year change?
- What is Kymera Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Kymera Therapeutics?
- What is Kymera Therapeutics TTM SG&A year-on-year change?
What is Kymera Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of KYMR is $55.04 M
What is the all time high annual SG&A for Kymera Therapeutics?
Kymera Therapeutics all-time high annual selling, general & administrative expenses is $55.04 M
What is Kymera Therapeutics annual SG&A year-on-year change?
Over the past year, KYMR annual selling, general & administrative expenses has changed by +$11.21 M (+25.57%)
What is Kymera Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of KYMR is $15.46 M
What is the all time high quarterly SG&A for Kymera Therapeutics?
Kymera Therapeutics all-time high quarterly selling, general & administrative expenses is $17.37 M
What is Kymera Therapeutics quarterly SG&A year-on-year change?
Over the past year, KYMR quarterly selling, general & administrative expenses has changed by +$1.33 M (+9.45%)
What is Kymera Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of KYMR is -$2.42 B
What is the all time high TTM SG&A for Kymera Therapeutics?
Kymera Therapeutics all-time high TTM selling, general & administrative expenses is $61.43 M
What is Kymera Therapeutics TTM SG&A year-on-year change?
Over the past year, KYMR TTM selling, general & administrative expenses has changed by -$2.47 B (-4704.94%)